Loading
NASDAQHealthcareBiotechnology
Latest quote
$157.24
+$1.77 · +1.14%
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Previous close
$157.24
+$1.77 · +1.14%
Pre-market
$156.68
−$0.56 · -0.36%
Sep 8, 7:10 AM ET
Regular session · ET · Market data may be delayed.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Day range
Current $157.24
52-week range
Current $157.24
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
61
Bullish
Risk
40
Moderate Risk
Momentum
73
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Day range
Current $157.24
52-week range
Current $157.24
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 25.9M USD | 31.42M USD |
| Cost of goods sold | — | — | — | 2.78M USD | 2.37M USD |
| Gross profit | — | — | — | 23.12M USD | 29.05M USD |
| Research and development | 22.84M USD | 8.15M USD | 8.79M USD | 50.21M USD | 64.2M USD |
| Selling, general, and administrative | 15.76M USD | 5.94M USD | 3.08M USD | 16.38M USD | 16.68M USD |
| Operating expenses | 38.6M USD | 14.1M USD | 11.87M USD | 66.6M USD | 80.88M USD |
| Interest income | 2.59M USD | 642K USD | 6.27M USD | 721K USD | 4K USD |
| Interest expense | 5.82M USD | 4.32M USD | — | — | — |
| Depreciation and amortization | — | — | — | 2.78M USD | 2.37M USD |
| Operating income | −38.6M USD | −14.1M USD | −11.87M USD | −43.47M USD | −51.83M USD |
| Net income | −41.72M USD | −17.43M USD | 18.69M USD | −33.28M USD | −45.74M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$232.25
47.70% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 23, 2024 | 1:80 | — | — |
Effective Apr 23, 2024
1:80
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI67.77M0.59%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI54.18M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM43.78M0.05%80.51B USD0.19%$296.01+0.28%
iShares Russell 2000 Growth ETFIWO15.81M0.11%14.7B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO8.56M0.05%17.4B USD0.06%$119.62+0.25%
Vanguard Health Care ETFVHT4.23M0.02%20.9B USD0.09%$321.66-0.97%
Vanguard U.S. Momentum Factor ETFVFMO3.51M0.18%1.8B USD0.13%$229.8+0.93%
ALPS Medical Breakthroughs ETFSBIO3.11M1.25%248.37M USD0.50%$67.66+0.52%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTVanguard U.S. Momentum Factor ETFVFMOALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
